Thursday, November 07, 2019 2:50:08 PM
Cannabis sativa exists in different chemical variants, showing chemical but sometimes also morphological differences, known as chemotypes (Small and Beckstead 1973). Three different principal chemotypes were first identified. The first one was defined as the ‘drug type’ (chemotype I), because its low CBD/THC content ratio, especially due to high THC content. The second chemotype, ‘intermediate’, has both the two main cannabinoids, THC and CBD, in a content ratio close to the unity (typically ranging from 0.5 to 3.0; chemotype II), but usually with a slight prevalence of CBD; the third one, the so-called ‘fibre’, or ‘non-drug’ type (chemotype III), has mainly CBD, an amount of THC lower than 0.3%, and therefore a high CBD/THC ratio, sometimes not calculable due to undetectability of THC (de Meijer et al. 1992). It has been recently demonstrated that all the three main chemotypes can arise simply by segregation at one locus (B) within individual F2 progenies of divergent-chemotype parentals (Mandolino et al. 2003; de Meijer et al. 2003). Today a widely accepted view of the inheritance of these three chemotypes, is based upon the occurrence, at B locus, of two codominant alleles, BD and BT, responsible for the presence of CBD and THC, respectively (de Meijer et al. 2003; Mandolino 2004).
Genetics and marker-assisted selection of the chemotype in Cannabis sativa L., Daniela Pacifico, Francesca Miselli, Mirta Micheler, Andrea Carboni, Paolo Ranalli and Giuseppe Mandolino; Molecular Breeding (2006) 17: 257–268.
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
